SEARCH

SEARCH BY CITATION

References

  • 1
    NIH Consensus Development Statement on Management of Hepatitis C: 2002. HEPATOLOGY 2002; 36( Suppl): S3S20.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958956.
  • 4
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al., for the PEGASYS International Study Group. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 5
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2 plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 6
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425433.
  • 7
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 8
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 26092617.
  • 9
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 12601265.
  • 10
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon alfa 2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522527.
  • 11
    Andriulli A, Dalgard O, Bjioro K, Mangia A. Short term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38: 741748.
  • 12
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solà R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124134.
  • 13
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficiency of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 14
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964970.
  • 15
    Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al., for the Benelux Study Group on Treatment of Chronic Hepatitis C. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689695.
  • 16
    Buti M, Valdes A, Sanchez-Avita F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa 2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases (letter). HEPATOLOGY 2003; 37: 12261227.
  • 17
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa 2a plus ribavirin. Gastroenterology 2006; 130: 10861097.
  • 18
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al., and the Tera ViC Study Group. Peginterferon alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451460.
  • 19
    Zeuzem S, Fried MW, Reddy R, Marcellin P, Diago M, Craxì A, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa 2a (40 KD) (Pegasys) plus ribavirin (Copegus). HEPATOLOGY 2006; 44: 267A.
  • 20
    Desmet V, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 15131520.
  • 21
    Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol 2005; 100: 868873.
    Direct Link:
  • 22
    Ferenci P, Bergholz U, Laferl H, Gurguta C, Aaieron A, Gschwantler H, et al. Is shorter treatment with peginterferon alfa-2 plus ribavirin possible in HCV genotype 1 “super-responders”? Preliminary results of a prospective randomized clinical trial. HEPATOLOGY 2005; 42( Suppl 1): 650.
  • 23
    Berg C, Goncales FL, Bernstein DE, Sette H, Rasenack J, Diago M, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alfa-2a and ribavirin. J Viral Hepat 2006; 13: 435440.
  • 24
    Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474481.
  • 25
    Fontana RJ. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? Gastroenterology 2006; 130: 13571362.